LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis
NASDAQ:LGND - Nasdaq - US53220K5048 - Common Stock - Currency: USD
Taking everything into account, LGND scores 5 out of 10 in our fundamental rating. LGND was compared to 193 industry peers in the Pharmaceuticals industry. LGND has an excellent financial health rating, but there are some minor concerns on its profitability. LGND is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
LGND had positive earnings in the past year.
LGND had a positive operating cash flow in the past year.
In multiple years LGND reported negative net income over the last 5 years.
LGND had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
LGND has a Return On Assets of -14.66%. This is in the better half of the industry: LGND outperforms 64.77% of its industry peers.
LGND's Return On Equity of -16.68% is fine compared to the rest of the industry. LGND outperforms 73.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.66% | ||
| ROE | -16.68% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of LGND has declined.
LGND has a better Gross Margin (92.81%) than 95.85% of its industry peers.
LGND's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LGND so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.81% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
LGND does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LGND has been increased compared to 1 year ago.
Compared to 5 years ago, LGND has more shares outstanding
LGND has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 16.59 indicates that LGND is not in any danger for bankruptcy at the moment.
LGND's Altman-Z score of 16.59 is amongst the best of the industry. LGND outperforms 89.12% of its industry peers.
LGND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.59 |
ROIC/WACCN/A
WACC9.53%
2.3 Liquidity
A Current Ratio of 5.27 indicates that LGND has no problem at all paying its short term obligations.
The Current ratio of LGND (5.27) is better than 73.06% of its industry peers.
LGND has a Quick Ratio of 5.02. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
LGND has a Quick ratio of 5.02. This is in the better half of the industry: LGND outperforms 73.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.27 | ||
| Quick Ratio | 5.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.80% over the past year.
Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.44% on average per year.
Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 27.28%.
Measured over the past years, LGND shows a small growth in Revenue. The Revenue has been growing by 6.80% on average per year.
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
Revenue 1Y (TTM)27.28%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.69%
3.2 Future
LGND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.04% yearly.
The Revenue is expected to grow by 17.40% on average over the next years. This is quite good.
EPS Next Y9.38%
EPS Next 2Y11.76%
EPS Next 3Y12.9%
EPS Next 5Y12.04%
Revenue Next Year18.79%
Revenue Next 2Y18.83%
Revenue Next 3Y17.92%
Revenue Next 5Y17.4%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 24.44, the valuation of LGND can be described as rather expensive.
Based on the Price/Earnings ratio, LGND is valued cheaper than 80.31% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.54, LGND is valued at the same level.
With a Price/Forward Earnings ratio of 20.70, LGND is valued on the expensive side.
LGND's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. LGND is cheaper than 74.09% of the companies in the same industry.
LGND's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 35.28.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.44 | ||
| Fwd PE | 20.7 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than 75.65% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 78.76% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.28 | ||
| EV/EBITDA | 134.6 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
LGND's earnings are expected to grow with 12.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.6
PEG (5Y)1.82
EPS Next 2Y11.76%
EPS Next 3Y12.9%
5. Dividend
5.1 Amount
No dividends for LGND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:LGND (8/8/2025, 1:26:33 PM)
147.62
+1.3 (+0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners99.56%
Inst Owner Change-1.22%
Ins Owners1.68%
Ins Owner Change5.26%
Market Cap2.85B
Analysts84.62
Price Target148.92 (0.88%)
Short Float %6.55%
Short Ratio8.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.12%
Min EPS beat(2)4.63%
Max EPS beat(2)7.61%
EPS beat(4)4
Avg EPS beat(4)19.05%
Min EPS beat(4)4.63%
Max EPS beat(4)33.98%
EPS beat(8)8
Avg EPS beat(8)51.69%
EPS beat(12)12
Avg EPS beat(12)75.63%
EPS beat(16)15
Avg EPS beat(16)61.86%
Revenue beat(2)2
Avg Revenue beat(2)11.2%
Min Revenue beat(2)7.56%
Max Revenue beat(2)14.84%
Revenue beat(4)4
Avg Revenue beat(4)17.81%
Min Revenue beat(4)7.56%
Max Revenue beat(4)24.96%
Revenue beat(8)8
Avg Revenue beat(8)13.27%
Revenue beat(12)11
Avg Revenue beat(12)16.78%
Revenue beat(16)14
Avg Revenue beat(16)15.04%
PT rev (1m)0%
PT rev (3m)0.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.29%
EPS NY rev (1m)0.41%
EPS NY rev (3m)0.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.44 | ||
| Fwd PE | 20.7 | ||
| P/S | 15.69 | ||
| P/FCF | 56.28 | ||
| P/OCF | 54.22 | ||
| P/B | 3.58 | ||
| P/tB | 11.52 | ||
| EV/EBITDA | 134.6 |
EPS(TTM)6.04
EY4.09%
EPS(NY)7.13
Fwd EY4.83%
FCF(TTM)2.62
FCFY1.78%
OCF(TTM)2.72
OCFY1.84%
SpS9.41
BVpS41.24
TBVpS12.82
PEG (NY)2.6
PEG (5Y)1.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.66% | ||
| ROE | -16.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.81% | ||
| FCFM | 27.88% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 5.46% | ||
| Cap/Sales | 1.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 288.25% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.27 | ||
| Quick Ratio | 5.02 | ||
| Altman-Z | 16.59 |
F-Score5
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
EPS Next Y9.38%
EPS Next 2Y11.76%
EPS Next 3Y12.9%
EPS Next 5Y12.04%
Revenue 1Y (TTM)27.28%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.69%
Revenue Next Year18.79%
Revenue Next 2Y18.83%
Revenue Next 3Y17.92%
Revenue Next 5Y17.4%
EBIT growth 1Y-1126.01%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year483.19%
EBIT Next 3Y133.64%
EBIT Next 5YN/A
FCF growth 1Y-51.53%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-56.16%
OCF growth 3Y7.19%
OCF growth 5YN/A